Neurogene Inc. Balance Sheet
NGNE|4 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 4 fiscal years. All figures from audited SEC 10-K filings.
Neurogene Inc. had $289M in total assets and $310M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.24 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2019 | FY2018 |
|---|---|---|---|---|
| Cash & Equivalents | $103.8M | $136.6M | $143.1M | $76.9M |
| Current Assets | $271.8M | $315.9M | $143.6M | $77.2M |
| PP&E (Net) | $12.8M | $15.4M | $2.1M | $400.0K |
| Total Assets | $288.6M | $335.7M | $147.0M | $77.6M |
| Current Liabilities | $16.4M | $15.2M | $4.7M | $4.6M |
| Shareholders' Equity | $310.4M | $186.0M | $72.7M | $144.7M |